COVID-19/SARS-COV-2 / RESEARCH LETTER
Could amantadine possibly interfere with COVID-19 vaccines based on LNP-mRNA platform ?
| 1 | Polish Hospital Fedeeration, Poland |
| 2 | Collegium Humanum Warsaw Management University, Poland |
| 3 | University of Vermont College of Medicine and Health Network, United States |
CORRESPONDING AUTHOR
Submission date: 2021-03-21
Acceptance date: 2021-03-21
Online publication date: 2021-03-28
Arch Med Sci 2021;17(3)
KEYWORDS
TOPICS
ABSTRACT
Introduction:
Amantadine is a well-known medication with indications in neurology and infectious diseases. It is currently FDA approved for Parkinson disease, drug induced extrapyramidal symptoms, and influenza.
Material and methods:
The article is author's original research hypothesis.
Results:
As more people are going to be vaccinated and more similar vaccines are going to be introduced, we should take into consideration a potential of amantadine to interfere with LNP-mRNA COVID-19 vaccine delivery into the target cells.
Conclusions:
A more cautious approach to the patients taking amantadine as far as vaccination utilizing LNP-mRNA platform should be considered.
Amantadine is a well-known medication with indications in neurology and infectious diseases. It is currently FDA approved for Parkinson disease, drug induced extrapyramidal symptoms, and influenza.
Material and methods:
The article is author's original research hypothesis.
Results:
As more people are going to be vaccinated and more similar vaccines are going to be introduced, we should take into consideration a potential of amantadine to interfere with LNP-mRNA COVID-19 vaccine delivery into the target cells.
Conclusions:
A more cautious approach to the patients taking amantadine as far as vaccination utilizing LNP-mRNA platform should be considered.
RELATED ARTICLE
